arrow
S

Satoshi Kamidani

Harvard Medical School
H指数:19
被引数:2,123

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics of young children hospitalized with acute respiratory failure from infection with RSV, SARS-CoV-2, or both, November 2023–March 2024

2023年11月至2024年3月,因感染呼吸道合胞病毒(RSV)、严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)或两者混合感染而住院的急性呼吸衰竭患儿的特征。

2026-03-040
OA
Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those with Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020

呼吸道合胞病毒住院率:≥50岁成人及充血性心力衰竭或慢性阻塞性肺疾病急性加重患者,2018-2020年

2026-02-240
PRE
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances

在COVID-19变体免疫学景观(COVAIL)试验中,中和抗体滴度与COVID-19风险的相关性未受SARS-CoV-2氨基酸序列距离的影响

Vaccine
IF3.5
2026-02-010
OAAI
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

与原型加强针mRNA疫苗接种相比,Omicron BA.1基线加强针mRNA疫苗接种对COVAIL试验中COVID-19发病率的影響

Vaccine
IF3.5
2025-09-090
OAAI
Viral Etiologies of Acute Respiratory Illness in Older Adults and of Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization During 2 Prepandemic Respiratory Seasons

老年人群急性呼吸道疾病的病毒病因,以及需要住院治疗的充血性心力衰竭和慢性阻塞性肺疾病急性加重的病毒病因,在2个疫情前呼吸道流行季节的研究

2025-07-010
PRE
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose
2024-12-230
OAAI
Relative Contribution of Diagnostic Testing to the Diagnosis of Respiratory Syncytial Virus in Hospitalized Adults in the United States

诊断测试对美国住院成人呼吸道合胞病毒诊断的相对贡献

2024-07-121
OAAI
Effectiveness of BNT162b2 Vaccine for Preventing COVID-19-Related Hospitalizations: A Test-Negative Case-Control Study
2024-06-132
OAAI
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

一项2期临床试验,用于评估在健康美国成年人中使用和不使用AS03佐剂的2013年和2017 A(H7N9) 灭活流感病毒疫苗的安全性,反应原性和免疫原性

2024-03-274
PRE
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
2024-03-276
PRE
Influenza Vaccine Effectiveness Pre-pandemic Among Adults Hospitalized With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease and Older Adults
2023-11-082
OA
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023-08-2819
OAAI
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
2023-08-101
OA
Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022

2021年11月至2022年3月对接受辉瑞-BioNTech新型冠状病毒肺炎疫苗的5-11岁美国儿童进行多系统炎症综合征监测

2023-02-233
OA
Maternal Vaccination and Risk of Hospitalization for Covid-19 Among Infants
2023-01-010
PRE
BNT162b2 mRNA Vaccination Against COVID-19 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021-April 2022
2022-08-2035
OA